Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incannex Healthcare Limited - American Depositary Shares (NQ: IXHL )

2.100 +0.090 (+4.48%)
Streaming Delayed Price Updated: 10:27 AM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,632
Open 2.090
Bid (Size) 1.860 (5)
Ask (Size) 2.090 (1)
Prev. Close 2.010
Today's Range 2.090 - 2.100
52wk Range 1.770 - 7.680
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary
Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd. 
Via Benzinga

Performance

YTD
-31.03%
-31.03%
1 Month
+1.94%
+1.94%
3 Month
-12.86%
-12.86%
6 Month
-48.40%
-48.40%
1 Year
-71.23%
-71.23%

More News

Read More
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
Via Benzinga
Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic
Via Benzinga
Why Incannex Healthcare Shares Are Gaining Today
Via Benzinga
Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products
Via Talk Markets
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
Via TheNewswire.com
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
Via News Direct
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Via Benzinga
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market
Via Benzinga
Largest Psychedelic Stocks -3.4% In March
Via Talk Markets
Cannabis Category Performances Ranged From +8.6% To -7.0% This Week
Via Talk Markets
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Via Benzinga
Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary
Via Benzinga
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Via Benzinga
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
All 5 Cannabis Categories Down Last Week; Only 1 Is UP YTD
Via Talk Markets
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
Via Benzinga
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
Via News Direct
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
Via TheNewswire.com
Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials
Via Benzinga
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial
Via TheNewswire.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.